Drug Trial Radar · NCT05383131
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jun 23, 2021
Primary completion
Nov 30, 2021
Study completion Nov 30, 2021
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open label study to evaluate drug-drug interactions between HEC585 and Pirfenidone or Nintedanib in healthy volunteers
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
HEC585Drug
Mulltiple doses of HEC585 for up to 10 days
PirfenidoneDrug
Mulltiple doses of Pirfenidone for up to 3 days
NintedanibDrug
Mulltiple doses of Nintedanib for up to 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of HEC585 and PirfenidoneTime frame: 0~96 hour
- AUC of HEC585 and PirfenidoneTime frame: 0~96 hour
- Cmax of HEC585 and NintedanibTime frame: 0~96 hour
- AUC of HEC585 and NintedanibTime frame: 0~96 hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.